Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294)

Market Cap	34.63B
Revenue (ttm)	3.72B
Net Income (ttm)	586.53M
Shares Out	1.09B
EPS (ttm)	0.53
PE Ratio	59.93
Forward PE	51.59
Dividend	0.50 (1.57%)
Ex-Dividend Date	Jun 19, 2024

Volume	3,782,986
Open	32.03
Previous Close	31.87
Day's Range	31.58 - 32.08
52-Week Range	23.50 - 34.01
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shenzhen Salubris Pharmaceuticals

Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also provides interventional medical devices for therapy of cardiovascular and cerebrovascular diseases, peripheral blood vessels, structural heart diseases, electrophysiol...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 3,517
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002294

Financial Performance

In 2023, Shenzhen Salubris Pharmaceuticals's revenue was 3.37 billion, a decrease of -3.35% compared to the previous year's 3.48 billion. Earnings were 580.07 million, a decrease of -8.95%.